Therapeutic Apheresis in Hyperleukocytosis and Hyperviscosity Syndrome

 

 Buy Article Permissions and Reprints

ABSTRACT

Therapeutic apheresis (TA), as a way of rapidly eliminating harmful or excessive blood components such as plasma proteins (plasma exchange) or cells (leukapheresis and platelet apheresis), has found broad application in a vast array of hematologic disorders. The most common hematologic indications for TA are leukocytosis in acute leukemias and hyperviscosity syndrome secondary to plasma cell dyscrasia. Leukapheresis is indicated in the initial management of leukostasis in patients with hyperleukocytosis in acute leukemias, particularly myeloid leukemias, or in patients who are at high risk of developing such a complication. Patients with lymphoid malignancies rarely develop leukostasis but may undergo cytoreduction with leukapheresis as prophylaxis for tumor lysis. The use of leukapheresis in acute promyelocytic leukemia is discouraged, given the possibility of increased risk of coagulopathy and bleeding. Similarly, therapeutic plasma exchange (TPE) represents an effective but temporary way of managing hyperviscosity syndrome secondary to immunoglobulin M paraproteins in patients with Waldenström macroglobulinemia. This review provides an overview of the pathophysiology of leukostasis and its management with leukapheresis. The use of TPE in the management of hyperviscosity syndrome is also discussed.

REFERENCES

• 1 Porcu P, Cripe L D, Ng E W et al.. Hyperleukocytic leukemias and leukostasis: a review of pathophysiology, clinical presentation and management.  Leuk Lymphoma. 2000;  39 1-18
  CrossrefPubMedGoogle Scholar
• 2 Vaughan W P, Kimball A W, Karp J E, Dragon L H, Burke P J. Factors affecting survival of patients with acute myelocytic leukemia presenting with high WBC counts.  Cancer Treat Rep. 1981;  65 1007-1013
  PubMedGoogle Scholar
• 3 Hug V, Keating M, McCredie K, Hester J, Bodey G P, Freireich E J. Clinical course and response to treatment of patients with acute myelogenous leukemia presenting with a high leukocyte count.  Cancer. 1983;  52 773-779
  CrossrefPubMedGoogle Scholar
• 4 Dutcher J P, Schiffer C A, Wiernik P H. Hyperleukocytosis in adult acute nonlymphocytic leukemia: impact on remission rate and duration, and survival.  J Clin Oncol. 1987;  5 1364-1372
  PubMedGoogle Scholar
• 5 Porcu P, Danielson C F, Orazi A, Heerema N A, Gabig T G, McCarthy L J. Therapeutic leukapheresis in hyperleucocytic leukaemias: lack of correlation between degree of cytoreduction and early mortality rate.  Br J Haematol. 1997;  98 433-436
  CrossrefPubMedGoogle Scholar
• 6 Creutzig U, Ritter J, Budde M, Sutor A, Schellong G. Early deaths due to hemorrhage and leukostasis in childhood acute myelogenous leukemia. Associations with hyperleukocytosis and acute monocytic leukemia.  Cancer. 1987;  60 3071-3079
  CrossrefPubMedGoogle Scholar
• 7 Bunin N J, Pui C H. Differing complications of hyperleukocytosis in children with acute lymphoblastic or acute nonlymphoblastic leukemia.  J Clin Oncol. 1985;  3 1590-1595
  PubMedGoogle Scholar
• 8 Bunin N J, Kunkel K, Callihan T R. Cytoreductive procedures in the early management in cases of leukemia and hyperleukocytosis in children.  Med Pediatr Oncol. 1987;  15 232-235
  CrossrefPubMedGoogle Scholar
• 9 Cuttner J, Holland J F, Norton L, Ambinder E, Button G, Meyer R J. Therapeutic leukapheresis for hyperleukocytosis in acute myelocytic leukemia.  Med Pediatr Oncol. 1983;  11 76-78
  PubMedGoogle Scholar
• 10 Ventura G J, Hester J P, Smith T L, Keating M J. Acute myeloblastic leukemia with hyperleukocytosis: risk factors for early mortality in induction.  Am J Hematol. 1988;  27 34-37
  CrossrefPubMedGoogle Scholar
• 11 Giles F J, Shen Y, Kantarjian H M et al.. Leukapheresis reduces early mortality in patients with acute myeloid leukemia with high white cell counts but does not improve long- term survival.  Leuk Lymphoma. 2001;  42 67-73
  CrossrefPubMedGoogle Scholar
• 12 Byrd J C, Mrozek K, Dodge R et al.. Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461).  Blood. 2002;  100 4325-4336
  CrossrefPubMedGoogle Scholar
• 13 Frohling S, Schlenk R F, Breitruck J et al.. Prognostic significance of activating FLT3 mutations in younger adults (16 to 60 years) with acute myeloid leukemia and normal cytogenetics: a study of the AML Study Group Ulm.  Blood. 2002;  100 4372-4380
  CrossrefPubMedGoogle Scholar
• 14 Vahdat L, Maslak P, Miller Jr W H et al.. Early mortality and the retinoic acid syndrome in acute promyelocytic leukemia: impact of leukocytosis, low-dose chemotherapy, PMN/RAR-alpha isoform, and CD13 expression in patients treated with all-trans retinoic acid.  Blood. 1994;  84 3843-3849
  PubMedGoogle Scholar
• 15 Wetzler M, Dodge R K, Mrozek K et al.. Prospective karyotype analysis in adult acute lymphoblastic leukemia: the cancer and leukemia Group B experience.  Blood. 1999;  93 3983-3993
  PubMedGoogle Scholar
• 16 Hoelzer D, Thiel E, Loffler H et al.. Prognostic factors in a multicenter study for treatment of acute lymphoblastic leukemia in adults.  Blood. 1988;  71 123-131
  PubMedGoogle Scholar
• 17 Estey E H, Keating M J, McCredie K B, Bodey G P, Freireich E J. Causes of initial remission induction failure in acute myelogenous leukemia.  Blood. 1982;  60 309-315
  PubMedGoogle Scholar
• 18 Byrd J C, Mrozek K, Dodge R K et al.. Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461).  Blood. 2002;  100 4325-4336
  CrossrefPubMedGoogle Scholar
• 19 Eguiguren J M, Schell M J, Crist W M, Kunkel K, Rivera G K. Complications and outcome in childhood acute lymphoblastic leukemia with hyperleukocytosis.  Blood. 1992;  79 871-875
  PubMedGoogle Scholar
• 20 Smith M, Arthur D, Camitta B et al.. Uniform approach to risk classification and treatment assignment for children with acute lymphoblastic leukemia.  J Clin Oncol. 1996;  14 18-24
  PubMedGoogle Scholar
• 21 Kuo K HM, Callum J, Brandwein J et al.. Management of hyperleukocytosis in acute myelogenous leukemia using hydroxyurea rather than leukopheresis.  Blood. 2006;  108 , (abst 2007)
  PubMedGoogle Scholar
• 22 McKee Jr L C, Collins R D. Intravascular leukocyte thrombi and aggregates as a cause of morbidity and mortality in leukemia.  Medicine (Baltimore). 1974;  53 463-478
  PubMedGoogle Scholar
• 23 Novotny J R, Nuckel H, Duhrsen U. Correlation between expression of CD56/NCAM and severe leukostasis in hyperleukocytic acute myelomonocytic leukaemia.  Eur J Haematol. 2006;  76 299-308
  CrossrefPubMedGoogle Scholar
• 24 Novotny J R, Muller-Beissenhirtz H, Herget-Rosenthal S, Kribben A, Duhrsen U. Grading of symptoms in hyperleukocytic leukaemia: a clinical model for the role of different blast types and promyelocytes in the development of leukostasis syndrome.  Eur J Haematol. 2005;  74 501-510
  CrossrefPubMedGoogle Scholar
• 25 Stucki A, Rivier A S, Gikic M, Monai N, Schapira M, Spertini O. Endothelial cell activation by myeloblasts: molecular mechanisms of leukostasis and leukemic cell dissemination.  Blood. 2001;  97 2121-2129
  CrossrefPubMedGoogle Scholar
• 26 Kwaan H C, Bongu A. The hyperviscosity syndromes.  Semin Thromb Hemost. 1999;  25 199-208
  Article in Thieme ConnectPubMedGoogle Scholar
• 27 Mehta J, Singhal S. Hyperviscosity syndrome in plasma cell dyscrasias.  Semin Thromb Hemost. 2003;  29 467-471
  Article in Thieme ConnectPubMedGoogle Scholar
• 28 Bachrach H J, Myers J B, Bartholomew W R. A unique case of kappa light-chain disease associated with cryoglobulinemia, pyroglobulinemia, and hyperviscosity syndrome.  Am J Med. 1989;  86 596-602
  CrossrefPubMedGoogle Scholar
• 29 Rosenson R S, McCormick A, Uretz E F. Distribution of blood viscosity values and biochemical correlates in healthy adults.  Clin Chem. 1996;  42 1189-1195
  PubMedGoogle Scholar
• 30 Drew M J. Plasmapheresis in the dysproteinemias.  Ther Apher. 2002;  6 45-52
  PubMedGoogle Scholar
• 31 Chirnside A, Urbaniak S J, Prowse C V, Keller A J. Coagulation abnormalities following intensive plasma exchange on the cell separator.  Br J Haematol. 1981;  48 627-634
  PubMedGoogle Scholar
• 32 Dodd R Y, Notari 4th E P, Stramer S L. Current prevalence and incidence of infectious disease markers and estimated window-period risk in the American Red Cross blood donor population.  Transfusion. 2002;  42 975-979
  CrossrefPubMedGoogle Scholar

William BlumM.D. 

The Ohio State University, B310 Starling Loving Hall

320 West 10th Ave., Columbus, OH 43210

Email: william.blum@osumc.edu